CJC-1295 & Ipamorelin Blend (10mg) – Premium Dual-Action GH Research Peptide

Welcome to Liaocheng Yixin Company, your trusted source for premium cjc-1295 ipamorelin 10mg blend for research. As a specialized peptide synthesis manufacturer operating from our facility at No. 9 Lushan Road, Dongcheng Street, Liaocheng Economic and Technological Development Zone, Shandong Province, we provide high-quality research compounds for the global scientific community.

This 10mg dual blend pairs CJC-1295 (without DAC, also known as Modified GRF 1-29) with Ipamorelin—the most extensively studied and widely cited GHRH+GHRP combination in research literature . CJC-1295 acts as a GHRH analog that engages the GHRH receptor on pituitary somatotrophs, while Ipamorelin activates the ghrelin receptor (GHS-R1a) with remarkable selectivity for growth hormone release. When paired, these peptides target complementary receptor systems, producing synergistic GH output that substantially exceeds the additive sum of either peptide alone . Our cjc-1295 ipamorelin 10mg blend for research offers investigators a convenient, precisely formulated tool for endocrine signaling, receptor pharmacology, and pulsatile GH research.

What is the CJC-1295 & Ipamorelin Blend?

This 10mg lyophilized blend contains two research peptides that work through complementary mechanisms at the hypothalamic-pituitary axis :

CJC-1295 without DAC is a tetrasubstituted GHRH analog with amino acid substitutions at positions 2, 8, 15, and 27 that protect it from rapid enzymatic degradation. Ipamorelin is a pentapeptide growth hormone secretagogue first characterized by Raun and colleagues in 1998 as a highly selective GHS-R1a agonist .cjc-1295 ipamorelin 10mg blend for research

Mechanism of Action in Research

The blend combines two distinct pathways to produce synergistic GH release :

GHRH Receptor Pathway (CJC-1295)

CJC-1295 binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled adenylyl cyclase signaling. This elevates intracellular cAMP, activates protein kinase A (PKA), and drives GH gene transcription and granule exocytosis. Without the Drug Affinity Complex (DAC), the peptide has a plasma half-life of approximately 30 minutes to 2 hours , producing discrete GH pulses that mimic endogenous pulsatile secretion.cjc-1295 ipamorelin 10mg blend for research

Ghrelin Receptor Pathway (Ipamorelin)

Ipamorelin activates GHS-R1a, a class A GPCR that couples primarily through Gq/11-alpha. This activates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium stores and activate protein kinase C (PKC). The calcium surge triggers immediate exocytosis of pre-formed GH vesicles .

Synergistic Amplification

The synergy between CJC-1295 and Ipamorelin is scientifically well-documented :

• Convergent Signaling: GHRH-pathway (cAMP/PKA) enhances GH synthesis and primes vesicles for release, while ghrelin-pathway (IP3/calcium) triggers rapid exocytosis.

• Multiplicative Effect: Co-activation produces a GH pulse substantially greater than the sum of individual responses.

• Reduced Somatostatin Tone: Ghrelin receptor activation antagonizes somatostatin signaling at the hypothalamic level, reducing the inhibitory tone that would otherwise limit GHRH-driven GH release.cjc-1295 ipamorelin 10mg blend for research

Ipamorelin Selectivity

The defining feature of Ipamorelin is its selectivity. Raun et al. (1998) demonstrated that Ipamorelin releases GH without significantly affecting ACTH, cortisol, prolactin, or FSH levels—even at doses more than 200-fold higher than the ED50 for GH release . This makes Ipamorelin the preferred pairing partner for researchers requiring a “clean” GH response .

Scientific Research Applications

Growth Hormone Secretagogue Research

The CJC-1295 and Ipamorelin blend is the most-cited GHRH+GHRP combination in research literature . It is studied for its ability to produce synergistic GH output through dual-pathway activation. The combination preserves natural GH rhythm while delivering amplified pulses—CJC-1295 increases GH pulse frequency, while Ipamorelin increases GH pulse amplitude .cjc-1295 ipamorelin 10mg blend for research

Pulsatile GH Physiology Research

The blend is designed to recapitulate physiological GH pulsatility rather than producing sustained, tonic GH elevation. Research on the somatotroph axis indicates that pulsatile GH exposure is more effective than continuous exposure for activating hepatic GH receptors and stimulating IGF-1 production . The short half-lives of both components (CJC-1295 no DAC ~30 min, Ipamorelin ~2 hours) naturally create pulse-like GH release kinetics .cjc-1295 ipamorelin 10mg blend for research

Selectivity and Receptor Bias Studies

Ipamorelin’s unique selectivity profile makes this blend valuable for investigating the effects of GH release without confounding cortisol or prolactin elevation. This selective profile distinguishes it from older GHRPs like GHRP-2 or GHRP-6, which raise cortisol and prolactin alongside GH .cjc-1295 ipamorelin 10mg blend for research

Body Composition Research

Investigations suggest this blend may influence energy metabolism through GH-mediated lipolysis and lipid oxidation pathways. Research also indicates potential modulation of glucose homeostasis, affecting energy balance and metabolic function. cjc-1295 ipamorelin 10mg blend for research

CJC-1295 Variant Comparison Research

Researchers use the no-DAC version of CJC-1295 to study pulsatile GH dynamics. The DAC variant carries a Drug Affinity Complex that extends half-life to roughly 5.8 to 8.1 days, producing sustained GHRH receptor stimulation . The no-DAC form, with its 30-minute to 2-hour half-life, is the typical pairing partner for Ipamorelin because their pulse timing matches .

Why Choose Liaocheng Yixin Company?

When sourcing cjc-1295 ipamorelin 10mg blend for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC analysis. Our blend meets ≥99% purity standards, with third-party testing and mass spectrometry identity confirmation . Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Components: CJC-1295 No DAC (GHRH) + Ipamorelin (GHRP)

• Appearance: White lyophilized powder

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture

• Form: Lyophilized powder for research use

• cjc-1295 ipamorelin 10mg blend for research

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. Mass Spectrometry for molecular weight confirmation

5. LAL Endotoxin Testing on every batch 

6. Packaged in sterile conditions for research use

: How does the CJC-1295 and Ipamorelin blend work in research?

A: CJC-1295 activates the GHRH receptor on pituitary somatotrophs through the cAMP/PKA pathway, while Ipamorelin engages the ghrelin receptor (GHS-R1a) through calcium mobilization. This dual-receptor activation produces synergistic GH output that substantially exceeds the additive sum of either peptide alone .

: What distinguishes Ipamorelin from other GHRPs?

A: Ipamorelin is the most selective ghrelin-receptor agonist studied. Raun et al. (1998) showed it produces GH release without elevating ACTH or cortisol, even at 200 times the effective GH-releasing dose . Older GHRPs like GHRP-2 and GHRP-6 raise cortisol, prolactin, and appetite, making Ipamorelin the preferred choice for researchers planning cleaner GH-axis research .

: What distinguishes CJC-1295 No DAC from the DAC version?

A: The DAC variant carries a Drug Affinity Complex that extends half-life to roughly 5.8 to 8.1 days, producing sustained GHRH receptor stimulation. The no-DAC variant has a 30-minute to 2-hour half-life and preserves a pulsatile pattern. The no-DAC form is the typical pairing partner for Ipamorelin because their pulse timing matches .

: Is there published human research on the CJC-1295 and Ipamorelin combination together?

A: No published human randomized trial has tested the CJC-1295 (no DAC) + Ipamorelin combination at the daily research doses. Each compound has its own human pharmacokinetic data, and cellular work supports a synergistic mechanism, but the blend itself has not been clinically trialed. For CJC-1295, Teichman 2006 in JCEM is the foundational human study; for Ipamorelin, Raun 1998 in the European Journal of Endocrinology is the key reference .

: What are the key research applications for this blend?

A: This blend is used in growth hormone secretagogue research (synergy studies), pulsatile GH physiology research, selectivity and receptor bias studies, and body composition research .cjc-1295 ipamorelin 10mg blend for research

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. This blend is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications .

When you need premium cjc-1295 ipamorelin 10mg blend for research for your endocrine, receptor pharmacology, or pulsatile GH studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust. cjc-1295 ipamorelin 10mg blend for research